CY1110716T1 - Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας - Google Patents

Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Info

Publication number
CY1110716T1
CY1110716T1 CY20101100718T CY101100718T CY1110716T1 CY 1110716 T1 CY1110716 T1 CY 1110716T1 CY 20101100718 T CY20101100718 T CY 20101100718T CY 101100718 T CY101100718 T CY 101100718T CY 1110716 T1 CY1110716 T1 CY 1110716T1
Authority
CY
Cyprus
Prior art keywords
viruses
cells
multiplication
implication
volume
Prior art date
Application number
CY20101100718T
Other languages
Greek (el)
English (en)
Inventor
Jürgen VORLOP
Christian Frech
Holger LÜBBEN
Jens-Peter Gregersen
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of CY1110716T1 publication Critical patent/CY1110716T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20101100718T 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας CY1110716T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144903A DE10144903A1 (de) 2001-09-12 2001-09-12 Vermehrung von Viren in Zellkultur
EP02777068A EP1427817B1 (de) 2001-09-12 2002-09-11 Vermehrung von viren in zellkultur

Publications (1)

Publication Number Publication Date
CY1110716T1 true CY1110716T1 (el) 2015-06-10

Family

ID=7698761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100718T CY1110716T1 (el) 2001-09-12 2010-07-30 Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας

Country Status (16)

Country Link
US (1) US20050118698A1 (cg-RX-API-DMAC10.html)
EP (1) EP1427817B1 (cg-RX-API-DMAC10.html)
JP (2) JP2005502357A (cg-RX-API-DMAC10.html)
KR (1) KR100968141B1 (cg-RX-API-DMAC10.html)
AT (1) ATE466932T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002338666B2 (cg-RX-API-DMAC10.html)
BR (1) BR0212469A (cg-RX-API-DMAC10.html)
CA (1) CA2456561A1 (cg-RX-API-DMAC10.html)
CY (1) CY1110716T1 (cg-RX-API-DMAC10.html)
DE (2) DE10144903A1 (cg-RX-API-DMAC10.html)
DK (1) DK1427817T3 (cg-RX-API-DMAC10.html)
ES (1) ES2345606T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ532203A (cg-RX-API-DMAC10.html)
PT (1) PT1427817E (cg-RX-API-DMAC10.html)
SI (1) SI1427817T1 (cg-RX-API-DMAC10.html)
WO (1) WO2003023025A1 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005245943A1 (en) * 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) * 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
KR20120083480A (ko) * 2009-10-20 2012-07-25 노파르티스 아게 바이러스 구제를 위한 개선된 역유전학 방법
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
AU2012217170B2 (en) * 2011-02-17 2016-07-28 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of PRRSV
EP2686423A4 (en) 2011-03-14 2015-01-28 Nat Res Council Canada Method of viral production in cells
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
US20150210986A1 (en) * 2012-08-24 2015-07-30 Ge Healthcare Bio-Sciences Corp. Virus purification and formulation process
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
CN105561317B (zh) * 2015-12-22 2018-03-20 肇庆大华农生物药品有限公司 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法
CN108239619A (zh) * 2016-12-23 2018-07-03 甘肃健顺生物科技有限公司 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术
CN108570445A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Pk15细胞驯化悬浮方法和二阶病毒生产工艺
CN108570444A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 St细胞驯化悬浮方法和二阶病毒生产工艺
CN108570454A (zh) * 2017-11-09 2018-09-25 甘肃健顺生物科技有限公司 Mdbk驯化悬浮方法和二阶病毒生产工艺
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
CN115927755A (zh) * 2022-11-22 2023-04-07 辽宁成大生物股份有限公司 一种微量水痘-带状疱疹病毒的检测方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
EP0878541A4 (en) * 1996-10-18 2001-10-17 Univ Osaka Res Found ROTAVIRUS ANTIGENS, VACCINALS AND MEDICATIONS AGAINST INFECTION BY ROTAVIRUS, AND METHOD FOR THEIR PRODUCTION
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
CA2401117C (en) * 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Also Published As

Publication number Publication date
WO2003023025A1 (de) 2003-03-20
DE50214416D1 (de) 2010-06-17
JP2005502357A (ja) 2005-01-27
AU2002338666B2 (en) 2008-11-20
NZ532203A (en) 2005-04-29
EP1427817B1 (de) 2010-05-05
EP1427817A1 (de) 2004-06-16
CA2456561A1 (en) 2003-03-20
DE10144903A1 (de) 2003-03-27
ES2345606T3 (es) 2010-09-28
ATE466932T1 (de) 2010-05-15
HK1062029A1 (zh) 2004-10-15
KR100968141B1 (ko) 2010-07-06
PT1427817E (pt) 2010-08-10
DK1427817T3 (da) 2010-08-23
JP2010246559A (ja) 2010-11-04
SI1427817T1 (sl) 2010-08-31
US20050118698A1 (en) 2005-06-02
BR0212469A (pt) 2004-08-24
KR20050027164A (ko) 2005-03-17

Similar Documents

Publication Publication Date Title
DE50214416D1 (de) Vermehrung von viren in zellkultur
WO2003023021A3 (de) Verfahren zur herstellung eines aktiven bestandteils eines arznei- oder diagnosemittels in mdck-zell-suspensionskultur
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
BR9610550A (pt) Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
ATE380822T1 (de) Funf-helix protein
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
EP2327722A3 (en) Mammalian genes involved in viral infection and tumor suppression
DE60132443D1 (de) In lebenden zielzellen
NO20032097D0 (no) Gj¶ravledet vaksine mot IPNV
WO2005092924A8 (en) Rab9a, rab11a, and modulators thereof related to infectious disease
ATE511397T1 (de) Lungenzellen von baumwollratten zur virenkultur
DE60331228D1 (de) Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
WO2007002172A3 (en) Hiv-1 protease inhibitors
EP1309342A4 (en) PREPARATION OF A CHIMERIC PAPILLOMA VIRUS (22.01.2)
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
TW200600006A (en) Method for cultivating cordyceps militaris fruiting body
JOHANRLILLEHAUG RNA splicing and SR protein phosphorylation under stress in acute myeloid leukemia (AML)
ES2105972A1 (es) Un procedimiento para la obtencion de modificadores de las respuestas biologicas con actividad recuperadora de la funcion hematopoyetica a partir, igual e indistintamente, de los cepas bacterianas fijadoras de n2 azotobacter chroococcum y azotobacter vinilandii.